ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc (XENE)

39,415
0,075
( 0,19% )
Mis à jour : 15:56:47

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
39,415
Prix Achat
39,25
Prix Vente
39,58
Volume échangé
21 633
38,71 Fourchette du Jour 39,87
28,2005 Plage de 52 semaines 50,99
Cap du marché
Clôture Veille
39,34
Ouverture
39,39
Dernière Transaction
53
@
39.387804
Dernière heure de transaction
15:57:37
Volume financier
US$ 853 265
VWAP
39,4428
Volume moyen (3 m)
360 586
Actions en circulation
76 239 602
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-16,44
Bénéfice par action (BPA)
-2,39
Chiffre d'affairess
-
Bénéfice net
-182,39M

À propos de Xenon Pharmaceuticals Inc

Founded in 1984, Xilinx is the leader in FPGAs by market share. Its chips are critical in the performance of various devices in the communications, data processing, industrial, consumer, and automotive markets. Founded in 1984, Xilinx is the leader in FPGAs by market share. Its chips are critical in the performance of various devices in the communications, data processing, industrial, consumer, and automotive markets.

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Burnaby, British Columbia, Can
Fondé
-
Xenon Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker XENE. Le dernier cours de clôture d'Xenon Pharmaceuticals était de US$39,34. Au cours de la dernière année, les actions de Xenon Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 28,2005 à US$ 50,99.

Xenon Pharmaceuticals compte actuellement 76 239 602 actions en circulation. La capitalisation boursière d'Xenon Pharmaceuticals est de US$3,00 milliard. Xenon Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -16.44.

XENE Dernières nouvelles

Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering...

Xenon Reports Q3 2024 Financial Results and Business Update

– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES –...

Xenon to Report Q3 2024 Financial Results on November 12, 2024

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering...

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE...

Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.555-6.0876816773941.9742.5637.3454617339.36061574CS
4-2.635-6.2663495838342.054637.3441303541.63162658CS
12-0.645-1.6100848726940.064637.3436058640.99091247CS
26-0.935-2.3172242874840.354635.5338924640.1993586CS
5210.32535.493296665529.0950.9928.200543598641.42816426CS
15610.52536.431291104228.8950.9923.2642752236.62144926CS
26030.275331.2363238519.1450.99743007731.66624991CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
WORXSCWorx Corporation
US$ 2,365
(141,33%)
69M
SKKSKK Holdings Limited
US$ 10,19
(123,46%)
878,71k
SPAISafe Pro Group Inc
US$ 4,9802
(55,63%)
31,58M
CRNCCerence Inc
US$ 4,3696
(54,95%)
5,96M
CDTConduit Pharmaceuticals Inc
US$ 0,1305
(41,39%)
373,55M
PYXSPyxis Oncology Inc
US$ 2,045
(-46,47%)
6,01M
KURAKura Oncology Inc
US$ 9,995
(-37,18%)
4,37M
BLRXBioLineRx Ltd
US$ 0,36989
(-32,16%)
4,04M
SHOTWSafety Shot Inc
US$ 0,11
(-26,67%)
1 000
TMTCTMT Acquisition Corporation
US$ 4,73
(-26,55%)
7,92k
CDTConduit Pharmaceuticals Inc
US$ 0,1296
(40,41%)
373,85M
AKTSAkoustis Technologies Inc
US$ 0,0942
(8,15%)
155,39M
NVDANVIDIA Corporation
US$ 146,39
(0,34%)
109,81M
WORXSCWorx Corporation
US$ 2,3695
(141,79%)
69,02M
ELABElevai Labs Inc
US$ 0,0204
(-4,67%)
46,86M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock